LOTTE BIOLOGICS Partners with AbTis on Next-Gen ADC Technology

• LOTTE BIOLOGICS has signed an MOU with AbTis to jointly advance antibody-drug conjugate (ADC) technology.

• The collaboration integrates AbTis’s AbClick® platform with LOTTE’s manufacturing capabilities at its Syracuse Bio Campus.

LOTTE BIOLOGICS, a contract development and manufacturing organisation (CDMO), has signed a Memorandum of Understanding (MOU) with AbTis, a specialist in antibody-drug conjugates (ADCs), to co-develop next-generation ADC technologies. The companies plan to combine AbTis’s AbClick® linker platform with LOTTE BIOLOGICS’ conjugation manufacturing capabilities at its Syracuse Bio Campus in New York.

The agreement aims to expand the scope of LOTTE BIOLOGICS’ ADC toolbox and increase competitiveness in the global market for ADC drug development and contract manufacturing. A feasibility assessment of the AbClick® platform is also scheduled at the Syracuse site to explore its practical application within LOTTE’s ADC workflow.

LOTTE BIOLOGICS currently provides flexible ADC services, including its proprietary SoluFlex Link™ platform, and supports clients with end-to-end CDMO offerings, from antibody development through to commercial-scale manufacturing.

AbTis’s AbClick® technology allows site-specific conjugation to the Fc domain of antibodies without genetic engineering, resulting in high product uniformity and consistent drug-to-antibody ratios.

James Park, CEO of LOTTE BIOLOGICS, stated: “This MOU will serve as a catalyst to maximise the technological strengths of both companies. We aim to contribute not only to the development of differentiated ADC therapies but also to improving the quality of life for patients around the world.”